Regenerex Pharma, Inc.
Regenerex Pharma, Inc. is a U.S.-based pharmaceutical preparations company focused on advanced wound care healing products. Its business centers on proprietary wound-closure technologies, including QBx™, for chronic, acute, and contamination-controlled wound treatment across medical care settings.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaProprietary technologies and formulations for chronic, acute, and contaminated wounds.
Clinical protocols and treatment pathways used with the company's wound products.
Core biologic ingredient designed to down-regulate proteases and support healing.
AI-enabled patient tracking and medication support software for wound care programs.
Partner-led commercialization, distributor development, and market access support.
Asiakkaat
Regenerex sells into healthcare payors and care-delivery organizations that manage chronic and acute wounds, especially where reimbursement and outcomes are tightly linked. Its target buyers include Medicaid programs, government-funded home care providers, veterans and correctional healthcare systems, private insurance networks, and wound care providers that need products and protocols to improve closure rates and reduce total treatment cost.
Buy wound care products and protocols to manage high-cost chronic wound populations at lower total cost.
Use wound closure products for aging patients with diabetic, pressure, and venous ulcers.
Seek preferred-provider arrangements and reimbursable wound care solutions that improve outcomes.
Includes VA and correctional facilities that need standardized wound protocols and cost control.
Purchase or distribute the company's products in Asia and the Middle East.
Strategia
Regenerex is focused on converting its wound-care technologies into reimbursable contracts with state Medicaid programs, government-funded providers, and private networks. It is also building international distributor relationships and adding digital wound-management capabilities to broaden its offering beyond a product-only model.
The business depends on payor access and contracted patient volume to commercialize wound products.
Distributor-led expansion can extend the addressable market without heavy owned infrastructure.
Clinical protocols and AI tools can support adoption, adherence, and reimbursement value.
Maantiede
Regenerex is headquartered in Tennessee and also maintains an office in Nevada, with operations organized around U.S. commercialization and outsourced manufacturing. The company is pursuing distribution and managed-care opportunities in southeastern U.S. states, Puerto Rico, Asia, and the Middle East, so its growth depends on both domestic reimbursement access and international distributor relationships.
Riskit
Regenerex is a development-stage healthcare company with no established revenue base, so execution depends on winning contracts, obtaining reimbursement access, and raising capital. Its business is also exposed to regulatory, clinical, and commercialization risk because wound-care products must prove efficacy, fit payor economics, and compete against established providers.
- Going-concern and financing riskVaikutus: KriittinenTodennäköisyys: Korkea
The company needs external capital to fund operations and commercialization before meaningful revenue is established.
Kohdistuu: Corporate liquidity and business continuity
- Commercialization and adoption riskVaikutus: KorkeaTodennäköisyys: Korkea
Healthcare buyers may be slow to adopt new wound-care protocols without strong clinical and economic proof.
Kohdistuu - Reimbursement and payor access riskVaikutus: Korkea
The business model relies on Medicaid, Medicare, and insurer coverage for wound-care adoption.
Kohdistuu - Cybersecurity and cash theft riskVaikutus: Korkea
A reported bank-account hacking incident shows exposure to fraud and treasury controls.
Kohdistuu: Cash management
- Competition riskVaikutus: KeskitasoTodennäköisyys: Korkea
The company competes with established wound-care and consumer product companies with scale and distribution.
Kohdistuu: Domestic and international wound-care markets
Kirjanpito
Harkinnanvaraiset erätFair value estimates can materially affect reported expenses in a company that uses equity financing.
Vaikutus: Expense recognition and equity dilution
The company acquired wound-healing technology platforms, so asset valuation and impairment are important.
Vaikutus: Balance sheet carrying value and amortization
Limited revenue and reliance on external funding make liquidity assumptions central to the financial statements.
Vaikutus: Disclosure and investor risk assessment
Headquarters and production infrastructure are leased, affecting liabilities and operating expense presentation.
Vaikutus: Right-of-use assets and lease liabilities
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
MiMedx Group, Inc
MDXG · Surgical & Medical Instruments & Apparatus
MIMEDX Group develops and commercializes regenerative biologic products used by clinicians to treat chronic wounds, burns, and surgical applications.
Organogenesis Holdings Inc.
ORGO · Pharmaceutical Preparations
RenovoRx, Inc.
RNXT · Surgical & Medical Instruments & Apparatus
Regen BioPharma Inc
RGBPP · Pharmaceutical Preparations
Regen BioPharma Inc is a U.S.-based biopharmaceutical development company organized in Nevada and operating through its wholly owned subsidiary KCL Therapeutics, Inc.
Bioregenx, Inc.
BRGX · Services-Computer Programming, Data Processing, Etc.
Regeneron Pharmaceuticals, Inc
REGN · Pharmaceutical Preparations
Regeneron Pharmaceuticals is a U.S.-based biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases.
Päivitetty: 24.9.2026